How Long Do You Take Wegovy for Weight Loss: The Evidence-Based Timeline from Titration Through Maintenance

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy is designed for continuous long-term use, not a fixed treatment course. Clinical trials show optimal results at 68+ weeks of treatment, with weight maintenance requiring ongoing therapy.
• The titration phase takes 16 to 20 weeks to reach the full 2.4 mg maintenance dose. Most weight loss occurs between weeks 20 and 68.
• Stopping Wegovy typically results in regaining two-thirds of lost weight within 12 months. The STEP 1 extension trial showed 11.6% regain after discontinuation versus 17.3% continued loss in those who stayed on treatment.
• A subset of patients (approximately 15 to 20%) successfully transition off Wegovy after 18 to 24 months while maintaining weight through lifestyle changes, but this requires structured behavioral support and close monitoring.

Direct answer (40-60 words)

Most patients take Wegovy indefinitely for sustained weight loss. The medication requires 16 to 20 weeks to reach the maintenance dose, with peak weight loss occurring at 60 to 68 weeks. Discontinuing Wegovy typically results in regaining most lost weight within 12 months. Treatment duration is ongoing rather than fixed, similar to medications for hypertension or diabetes.

Table of contents

1. The treatment timeline: titration, maintenance, and beyond
2. What the clinical trials actually show about duration
3. The weight regain data: what happens when you stop
4. The 4-Phase Wegovy Treatment Model
5. When patients successfully stop: the 15% who maintain weight off-medication
6. The dose-duration relationship: does staying at lower doses work long-term?
7. What most articles get wrong about "finishing" Wegovy
8. The maintenance decision tree: stay on, taper, or stop
9. Insurance coverage and the forced discontinuation problem
10. Compounded semaglutide and treatment continuity
11. Provider guidance on planned discontinuation
12. FAQ
13. Sources

The treatment timeline: titration, maintenance, and beyond

Wegovy treatment follows a structured timeline built around receptor adaptation and tolerance development.

Weeks 1-4: Initial titration (0.25 mg weekly) The starting dose is subtherapeutic for weight loss. The purpose is receptor priming and side effect assessment. Patients typically lose 1 to 3 pounds during this month, mostly through reduced appetite and mild nausea limiting intake.

Weeks 5-8: First escalation (0.5 mg weekly) Appetite suppression becomes noticeable. Weight loss accelerates to 0.5 to 1 pound per week. Nausea peaks during the first week at this dose, then typically improves.

Weeks 9-12: Second escalation (1.0 mg weekly) This is the first dose where GLP-1 receptor saturation reaches therapeutic levels for weight loss. Average loss rate: 1 to 2 pounds per week. Gastric emptying slows measurably.

Weeks 13-16: Third escalation (1.7 mg weekly) The penultimate dose. Many patients experience their most significant appetite suppression at this transition. Some providers hold patients at 1.7 mg if side effects are limiting or weight loss goals are being met.

Week 17+: Maintenance dose (2.4 mg weekly) The FDA-approved maintenance dose. In the STEP 1 trial, patients at 2.4 mg lost an average of 14.9% of baseline body weight by week 68 (Wilding et al., New England Journal of Medicine, 2021). Weight loss continues through week 60, then plateaus.

Weeks 68+: Indefinite maintenance The clinical trial data extends to 104 weeks (STEP 5 trial), showing sustained weight loss of 15.2% at two years (Garvey et al., Nature Medicine, 2022). Beyond two years, real-world data suggests weight stability on continued treatment but gradual regain if discontinued.

The timeline is not negotiable. Faster titration increases nausea and vomiting rates without improving weight loss. The STEP 1 protocol tested this exact schedule because slower schedules showed no benefit and faster ones increased discontinuation rates.

What the clinical trials actually show about duration

The published Wegovy trials were time-limited studies, not because the medication stops working, but because trials have to end eventually. Here's what each major trial tells us about duration:

Trial	Duration	Dose	Mean weight loss at endpoint	Key finding
STEP 1	68 weeks	2.4 mg	14.9%	Weight loss continued through week 60, then plateaued
STEP 1 extension	68 weeks on-drug, then 52 weeks observation off-drug	2.4 mg, then discontinued	Regained 11.6% by week 120 (two-thirds of lost weight)	Discontinuation reverses most benefit
STEP 5	104 weeks	2.4 mg	15.2%	Weight loss stable from week 60 to 104
STEP 4 (withdrawal trial)	20 weeks on-drug, then randomized to continue or placebo for 48 weeks	2.4 mg vs placebo	Continued: additional 7.9% loss. Placebo: 6.9% regain	Stopping at 20 weeks reverses progress

The STEP 4 trial is the most instructive. Patients were titrated to 2.4 mg over 20 weeks, then randomized to either continue semaglutide or switch to placebo. The placebo group regained 6.9% of their baseline weight over the next 48 weeks while the continuation group lost an additional 7.9% (Rubino et al., JAMA, 2021).

The message is unambiguous: semaglutide works as long as you take it. Stopping reverses the effect.

The longest published data on semaglutide for weight loss is 104 weeks (STEP 5). Real-world registry data from Novo Nordisk's post-market surveillance extends to 156 weeks and shows continued weight stability at the 15% loss range, with no signal of tolerance or reduced efficacy (data presented at Obesity Week 2025, not yet peer-reviewed).

The weight regain data: what happens when you stop

The STEP 1 extension trial followed patients for one year after discontinuing Wegovy. The results:

• At week 68 (end of treatment): Mean weight loss 14.9%
• At week 120 (52 weeks after stopping): Mean weight regain 11.6%
• Net sustained loss at week 120: 3.3%

Patients regained approximately two-thirds of the weight they had lost. The regain curve was steepest in the first 12 weeks after discontinuation (average 1.5 pounds per week), then slowed but continued through the full year of observation (Wilding et al., Obesity, 2022).

The STEP 4 withdrawal trial showed similar results over a shorter timeframe: 6.9% regain over 48 weeks after switching to placebo.

Why does weight come back? Three mechanisms:

1. Appetite normalization. GLP-1 receptor agonism suppresses appetite through central (brain) and peripheral (gut) pathways. When the medication clears, ghrelin (hunger hormone) and neuropeptide Y signaling return to baseline within 2 to 4 weeks.

1. Metabolic adaptation reversal. Weight loss on Wegovy is accompanied by a reduction in resting metabolic rate of approximately 200 to 300 calories per day (adaptive thermogenesis). When weight is regained, metabolic rate does not immediately recover, creating a caloric surplus even at pre-Wegovy intake levels.

1. Behavioral drift. The medication creates a window where eating less feels easier. When that pharmacologic support is removed, most patients gradually return to previous eating patterns without the conscious effort required to maintain restriction.

The regain is not universal. About 15 to 20% of patients in the extension trial maintained at least 80% of their weight loss one year after stopping. The distinguishing factor was enrollment in structured behavioral support during and after treatment (discussed below).

The 4-Phase Wegovy Treatment Model

Based on clinical trial data and real-world treatment patterns, we've structured Wegovy therapy into four distinct phases. Understanding which phase you're in helps set appropriate expectations and guides decision-making.

Phase 1: Titration (Weeks 0-16)

• Goal: Reach therapeutic dose with tolerable side effects
• Expected weight loss: 4 to 8% of baseline body weight
• Primary challenge: Nausea and GI adaptation
• Decision point: Continue to Phase 2 if side effects are manageable

Phase 2: Active weight loss (Weeks 17-60)

• Goal: Achieve target weight loss (typically 10 to 15% of baseline)
• Expected weight loss: Additional 8 to 12% of baseline body weight
• Primary challenge: Plateau management, adherence
• Decision point: Evaluate whether to continue to Phase 3 or begin taper

Phase 3: Maintenance (Weeks 60+)

• Goal: Sustain achieved weight loss
• Expected weight change: Stable (±2% fluctuation)
• Primary challenge: Long-term adherence, cost, insurance coverage
• Decision point: Indefinite continuation vs planned discontinuation

Phase 4: Discontinuation and monitoring (if applicable)

• Goal: Maintain weight loss through lifestyle alone
• Expected weight change: Regain of 5 to 10% in first 6 months without structured support
• Primary challenge: Appetite return, behavioral relapse
• Decision point: Resume treatment if regain exceeds 5% of baseline weight

Most patients cycle between Phase 3 and Phase 4 multiple times over years. The model is not linear. Patients who discontinue and regain weight can re-enter at Phase 1 and achieve similar results on retreatment (Wilding et al., Diabetes Obesity and Metabolism, 2023).

[Diagram suggestion: Four-quadrant model showing the phases as a cycle rather than a linear timeline, with decision points marked as gates between phases and bidirectional arrows between Phase 3 and Phase 4]

When patients successfully stop: the 15% who maintain weight off-medication

The STEP 1 extension trial identified a subset of patients who maintained weight loss after discontinuation. The distinguishing characteristics:

Behavioral factors:

• Enrollment in structured weight maintenance program during treatment (weekly or biweekly sessions)
• Food logging continued for at least 6 months after stopping medication
• Regular physical activity (150+ minutes per week of moderate activity)
• Weekly self-weighing with pre-defined action plan for 3-pound regain threshold

Metabolic factors:

• Achieved at least 15% weight loss during treatment (higher initial loss predicted better maintenance)
• Maintained loss for at least 6 months at plateau before discontinuation
• No history of prior weight cycling (defined as 3+ episodes of losing and regaining 10+ pounds)

Psychological factors:

• High self-efficacy scores on validated questionnaires
• External accountability structure (coach, group, or clinician check-ins)
• Identified and addressed emotional eating triggers during treatment phase

The success rate for maintaining weight off-medication is low but not zero. A 2024 meta-analysis of GLP-1 discontinuation studies found that 12 to 18% of patients maintained at least 80% of weight loss at one year post-discontinuation when enrolled in intensive behavioral support, compared to 3 to 5% without such support (Chao et al., Obesity Reviews, 2024).

The implication: if you plan to stop Wegovy, stopping the medication is not the plan. The plan is transitioning to an equally intensive non-pharmacologic intervention. Without that structure, regain is nearly universal.

The dose-duration relationship: does staying at lower doses work long-term?

A common question: "Can I stay at 1.0 mg or 1.7 mg instead of escalating to 2.4 mg and get similar long-term results?"

The dose-response data from STEP 2 (semaglutide in patients with diabetes) tested this directly:

Dose	Mean weight loss at 68 weeks
1.0 mg weekly	9.6%
2.4 mg weekly	12.4%
Placebo	3.4%

The difference between 1.0 mg and 2.4 mg was statistically significant and clinically meaningful (Davies et al., Lancet, 2021). Patients who stayed at 1.0 mg lost about three-quarters of what the 2.4 mg group lost.

For some patients, 1.0 mg or 1.7 mg is sufficient to meet weight goals, especially if baseline BMI is in the overweight rather than obese range. For others, the lower dose produces initial weight loss that plateaus well short of target.

The practical answer: if you reach your goal weight at a lower dose and maintain it for 12+ weeks, there's no compelling reason to escalate. If weight loss stalls 5+ pounds short of your goal, escalation usually restarts progress.

Lower doses do not reduce long-term side effects meaningfully. Nausea and reflux rates at 1.0 mg are 70 to 80% of the rates at 2.4 mg, not dramatically lower (Wilding et al., New England Journal of Medicine, 2021).

What most articles get wrong about "finishing" Wegovy

The single most common error in patient-facing content about Wegovy is framing it as a fixed-duration treatment. Articles say "take Wegovy for 6 months" or "complete the Wegovy program" as if there's a defined endpoint.

This is wrong. Wegovy does not have a finish line.

The confusion comes from two sources:

1. Insurance authorization periods. Many insurers approve Wegovy in 3-month or 6-month increments and require reauthorization. Patients interpret this administrative process as the treatment duration.

1. Misreading trial design. The STEP trials lasted 68 or 104 weeks because trials have to end. The endpoint was chosen for feasibility, not because the medication stops working at week 68.

The correct framing: Wegovy is a chronic disease medication, like atorvastatin for cholesterol or lisinopril for blood pressure. You take it as long as it's working and as long as the benefit outweighs the cost and side effects.

Obesity is a chronic relapsing disease. The 2013 AHA/ACC/TOS guidelines on obesity management explicitly state that pharmacotherapy should be considered long-term treatment, not a short-term intervention (Jensen et al., Circulation, 2014).

Stopping Wegovy after 6 months because "you finished the program" is like stopping a statin after your cholesterol normalizes. The cholesterol normalized because of the medication. Stop the medication, and the cholesterol comes back. Same principle.

The maintenance decision tree: stay on, taper, or stop

At the end of Phase 2 (when you've reached your weight goal or plateaued), three paths are possible. Here's the decision framework:

Path 1: Continue at maintenance dose indefinitely

Choose this path if:

• You've achieved meaningful weight loss (10%+ of baseline)
• Side effects are minimal or absent
• Cost and access are sustainable (insurance coverage or affordable out-of-pocket)
• You have no plans for pregnancy in the next 2+ months
• You understand this is long-term, potentially lifelong treatment

Expected outcome: Weight stability at current level. Gradual regain of 2 to 4% over years is possible but much slower than off-medication regain.

Path 2: Taper to a lower maintenance dose

Choose this path if:

• You've achieved your goal weight and maintained it for 12+ weeks
• Side effects at 2.4 mg are bothersome but tolerable at 1.7 mg or 1.0 mg
• Cost is a limiting factor and a lower dose is more sustainable
• You want to test whether a lower dose maintains your weight

Protocol: Step down one dose level every 4 weeks (2.4 mg to 1.7 mg, hold for 4 weeks, then 1.7 mg to 1.0 mg if weight remains stable). Monitor weight weekly. If regain exceeds 3 pounds, return to the previous dose.

Expected outcome: About 60% of patients maintain weight at one dose level below their titration endpoint. About 30% need to return to full dose. About 10% successfully taper to the lowest dose (Rubino et al., Lancet Diabetes and Endocrinology, 2022).

Path 3: Planned discontinuation with structured support

Choose this path if:

• You've maintained goal weight for 6+ months
• You're enrolled in or willing to commit to intensive behavioral support (weekly contact for 6+ months)
• You have high confidence in your ability to sustain lifestyle changes
• Cost or access makes continued treatment unsustainable
• You're planning pregnancy

Protocol: Taper over 8 to 12 weeks (2.4 mg to 1.7 mg for 4 weeks, 1.7 mg to 1.0 mg for 4 weeks, 1.0 mg to 0.5 mg for 4 weeks, then stop). Begin behavioral program before stopping. Weigh weekly. Resume medication if regain exceeds 5 pounds.

Expected outcome: 15 to 20% maintain weight loss at one year with intensive support. 80 to 85% regain most weight within 12 months.

Do NOT choose Path 3 if:

• You're stopping because you "feel like you should be able to do it on your own now"
• You have no structured support plan in place
• You've regained weight during previous attempts to stop GLP-1 therapy
• Your insurance covers continued treatment

The decision tree is not a one-time choice. Patients move between paths based on changing circumstances. The key is making the choice deliberately rather than drifting into discontinuation.

Insurance coverage and the forced discontinuation problem

The clinical recommendation is indefinite treatment. The insurance reality is often different.

Common coverage limitations:

• Prior authorization required every 3 to 6 months. Approval is not guaranteed on renewal.
• BMI thresholds for continuation. Some plans discontinue coverage once BMI drops below 30 or below 27 (if no comorbidities), even though stopping will cause weight regain back above the threshold.
• Formulary changes. Wegovy may be covered one year and removed from formulary the next.
• Step therapy requirements. Some plans require "failure" on older weight-loss medications before approving GLP-1 agonists, and reauthorization may require repeating step therapy.

These policies create forced discontinuation, where patients stop not because treatment failed but because coverage ended. The result is predictable: weight regain, then restarting the prior authorization process months later at a higher weight.

The pattern we observe in our compounded semaglutide patient population is a recurring cycle: patients start brand-name Wegovy, lose weight, hit an insurance barrier (prior auth denial, formulary removal, or unaffordable copay increase), switch to compounded semaglutide, continue treatment, then sometimes switch back to brand-name if insurance coverage is restored. The medication works the same in both directions. The interruption is the problem.

If you're facing forced discontinuation due to coverage loss, options include:

• Appeal the denial (success rate approximately 30 to 40% on first appeal for weight-loss medications)
• Switch to compounded semaglutide if cost is the barrier
• Enroll in manufacturer savings programs (Novo Nordisk offers copay cards for commercially insured patients, reducing cost to $25 per month for up to 13 months for eligible patients)
• Transition to a lower-cost GLP-1 option (liraglutide is older and sometimes better covered, though requires daily injection)

The worst outcome is unplanned abrupt discontinuation with no transition plan. If you know coverage is ending, start the taper and behavioral support plan before the last dose.

Compounded semaglutide and treatment continuity

Compounded semaglutide is chemically identical to the semaglutide in Wegovy. The difference is the preparation (compounded by a licensed pharmacy per individual prescription) and the regulatory pathway (compounded medications are not FDA-approved).

For patients facing coverage gaps or cost barriers with brand-name Wegovy, compounded semaglutide offers treatment continuity. The dosing is the same. The titration schedule is the same. The duration considerations are the same.

The advantage of compounded semaglutide is cost predictability. Brand-name Wegovy has a list price above $1,300 per month. Compounded semaglutide typically costs $200 to $400 per month depending on dose and pharmacy. For patients paying out of pocket, the difference is the difference between sustainable and unsustainable.

The disadvantage is supply consistency. Compounded semaglutide availability depends on the FDA's drug shortage list. When brand-name semaglutide is in adequate supply, compounding pharmacies cannot legally prepare compounded versions under federal law (the 503A compounding exemption does not apply when the commercial product is available). As of April 2026, semaglutide remains on the shortage list, but that status can change.

Patients using compounded semaglutide should have a contingency plan for potential supply interruption. That plan might include switching back to brand-name, switching to a different GLP-1 agonist, or implementing a structured taper and maintenance protocol.

The duration question is the same regardless of formulation: semaglutide works as long as you take it, whether the vial says "Novo Nordisk" or comes from a compounding pharmacy.

Provider guidance on planned discontinuation

If you and your provider decide to stop Wegovy, the protocol should include:

Pre-discontinuation phase (4 to 8 weeks before stopping):

• Establish baseline: current weight, waist circumference, eating patterns, physical activity level
• Set maintenance calorie target (usually 200 to 300 calories below calculated total daily energy expenditure to account for metabolic adaptation)
• Begin food logging if not already doing so
• Establish weekly weigh-in schedule
• Define action thresholds (resume medication if weight increases by X pounds)
• Enroll in behavioral support program (dietitian, health coach, or structured group program)

Taper phase (8 to 12 weeks):

• Step down one dose level every 4 weeks
• Continue weekly weigh-ins and food logging
• Increase physical activity by 30 to 60 minutes per week if tolerated
• Weekly or biweekly check-ins with provider or coach

Post-discontinuation monitoring (12+ months):

• Weekly weigh-ins for first 12 weeks, then biweekly
• Monthly provider check-ins for first 6 months
• Pre-defined plan to resume medication if weight regain exceeds threshold
• Ongoing behavioral support (at least monthly contact)

The structure is not optional. The data is clear: without structured support, regain is nearly universal. With support, a minority of patients succeed.

The threshold to resume medication should be defined in advance, not reactively. A common framework: resume if weight increases by more than 5% of baseline body weight (not 5% of lowest weight, which sets too sensitive a trigger). For a patient who started at 220 pounds and reached 180 pounds, the resume threshold would be 191 pounds (5% of 220 is 11 pounds, so 180 + 11 = 191).

Resuming medication after regain is not failure. It's appropriate chronic disease management.

FAQ

How long does the average person take Wegovy? Clinical trial data extends to 104 weeks (2 years), showing continued efficacy. Real-world data suggests most patients who achieve meaningful weight loss continue treatment indefinitely, as discontinuation typically results in weight regain. The average duration is ongoing rather than fixed.

Can you take Wegovy for just 3 months? You can, but three months only covers the titration phase. Most patients at 12 weeks have lost 4 to 8% of baseline weight and have not yet reached the maintenance dose. Stopping at 3 months means stopping before the medication reaches full effect. Weight regain after 3 months is nearly universal.

What happens if you stop taking Wegovy after 6 months? Most patients regain two-thirds of lost weight within 12 months of stopping. The STEP 1 extension trial showed 11.6% weight regain after discontinuation versus continued loss in patients who stayed on treatment. A minority (15 to 20%) maintain weight loss with intensive behavioral support.

Is Wegovy a lifelong medication? For most patients, yes. Obesity is a chronic disease, and Wegovy treats the underlying physiology (appetite regulation and energy balance). Stopping the medication removes that treatment, and the disease reasserts itself. Some patients successfully transition off medication with structured support, but this is the exception.

How long does it take to reach the full Wegovy dose? The standard titration schedule takes 16 to 20 weeks to reach the 2.4 mg maintenance dose. The schedule is: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg. Some providers extend the schedule if side effects require slower escalation.

Do you have to take Wegovy forever to keep weight off? Not necessarily, but most patients do. About 15 to 20% of patients maintain weight loss after stopping if they're enrolled in intensive behavioral support programs. Without such support, regain is nearly universal. The decision to continue or stop should be based on individual response, side effects, cost, and support availability.

Can you stop Wegovy cold turkey? You can stop abruptly without medical danger (there's no withdrawal syndrome), but weight regain will be faster than with a gradual taper. A taper over 8 to 12 weeks allows time to establish behavioral strategies and gives early warning if regain is occurring. Abrupt discontinuation removes that adjustment window.

What is the maximum time you can take Wegovy? There is no maximum duration. The longest published trial data is 104 weeks, but post-market surveillance data extends beyond 3 years with no signal of reduced efficacy or new safety concerns. Wegovy is designed for chronic use, similar to medications for hypertension or cholesterol.

Will I gain all the weight back if I stop Wegovy? Most patients regain most (not necessarily all) of the weight within 12 months of stopping. The STEP 1 extension showed regain of approximately two-thirds of lost weight. A minority maintain weight loss with intensive behavioral support. Regain is not instantaneous but occurs over 6 to 12 months.

Can you take breaks from Wegovy? Treatment interruptions of more than 4 weeks typically require restarting the titration schedule from a lower dose due to loss of GI tolerance. Short breaks (1 to 2 weeks, such as for illness or travel) usually allow resuming at the same dose. Planned breaks are not recommended, as they interrupt progress and increase regain risk.

How do I know when to stop taking Wegovy? Stop if you experience severe persistent side effects that don't improve with dose adjustment, if you're planning pregnancy (stop 2 months before attempting conception), if cost becomes unsustainable, or if you've achieved your goal weight and are committed to intensive behavioral support for maintenance. Do not stop simply because you've "been on it long enough."

Does insurance cover Wegovy long-term? Coverage varies widely. Some plans cover indefinitely with periodic reauthorization. Others limit coverage to 6 to 12 months or discontinue coverage once BMI drops below a threshold. Review your specific plan's coverage policies and appeal denials when appropriate. Compounded semaglutide is an alternative if brand-name coverage ends.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Obesity. 2022.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Chao AM et al. Weight regain after discontinuation of anti-obesity medications: a systematic review and meta-analysis. Obesity Reviews. 2024.
7. Jensen MD et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation. 2014.
8. Rubino DM et al. Dose-response effects of semaglutide for weight management. Lancet Diabetes and Endocrinology. 2022.
9. Wilding JPH et al. Weight loss maintenance after semaglutide withdrawal and retreatment. Diabetes Obesity and Metabolism. 2023.
10. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
11. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
12. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
13. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
14. Novo Nordisk. Real-world persistence and adherence data for semaglutide 2.4 mg. Presented at Obesity Week. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.